Metacrine, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Metacrine, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with gastrointestinal and liver diseases. The company offers a proprietary library of approximately 2,500 farnesoid X receptor (FXR) compounds; its lead product candidate MET642, an orally delivered FXR agonist that has completed Phase I clinical trials for ulcerative colitis and is Phase 2-ready for inflammatory bowel disease including ulcerative colitis and Crohn's disease; and a hydroxysteroid dehydrogenase 17B13 (HSD17B13) program targeting non-alcoholic steatohepatitis and other liver diseases. Metacrine was founded in 2014 and previously headquartered in San Diego, California. In 2022, Equillium, Inc. acquired Metacrine in an all-stock transaction valued at approximately $26 million, adding $33 million in cash to Equillium's balance sheet and extending its runway into 2024, with MET642 integrated into Equillium's pipeline for potential strategic partnerships; subsequently, Organovo has acquired the FXR program from the combined entity.
Company News
Trading Penny Stocks Under $1: Strategies for Succes & 7 To Watch
Metacrine: Potential Play On A Higher Bid
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOTZ, ECOM, MTCR, MNRL
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, SGFY, EQ, MTCR
Metacrine To Slash Its Workforce By 50%
Is the Options Market Predicting a Spike in Metacrine (MTCR) Stock?
3 Penny Stocks To Watch After Jerome Powell's Fed Announcement
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn's and Colitis Organisation (ECCO) 2021 Virtual Congress
Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021
Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH
Metacrine to Present at 2021 Jefferies Healthcare Conference
Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meeting
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis
Metacrine to Present at 2021 RBC Global Healthcare Conference